Professor | Jing Yang | Asia Growth Partners

Name	Jing Yang
Contact Information	jingy@tongji.edu.cn
Language ability	Chinese, English
Province	Shanghai

Name

Jing Yang

Contact Information

jingy@tongji.edu.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Tongji University
Faculty	Life Sciences
Academic Background & Achievements	2009 - Bachelor of Science: Shandong University 2015 - Doctor of Science: Shanghai Pasteur Institute, Chinese Academy of Sciences Received national grants, member of the Chinese Academy of Sciences Youth Innovation Promotion Association
Work Experience	2015-2020 - Dana-Farber Cancer Institute, Harvard Medical School: Postdoctoral Training 2021 Jan-Aug 2022 - Hefei Institutes of Physical Science, Chinese Academy of Sciences: Associate Researcher Since Sep 2022 - Tongji University, School of Life Sciences and Technology: Distinguished Researcher Since Jan 2023 - Tongji Hospital, Shanghai: Researcher

University/Lab Affiliation and Title

Tongji University

Faculty

Life Sciences

Academic Background & Achievements

2009 - Bachelor of Science: Shandong University
2015 - Doctor of Science: Shanghai Pasteur Institute, Chinese Academy of Sciences
Received national grants, member of the Chinese Academy of Sciences Youth Innovation Promotion Association

Work Experience

2015-2020 - Dana-Farber Cancer Institute, Harvard Medical School: Postdoctoral Training
2021 Jan-Aug 2022 - Hefei Institutes of Physical Science, Chinese Academy of Sciences: Associate Researcher
Since Sep 2022 - Tongji University, School of Life Sciences and Technology: Distinguished Researcher
Since Jan 2023 - Tongji Hospital, Shanghai: Researcher

Areas of Focus	Targeted and immunotherapy for malignant diseases such as leukemia Discovery and development of degrading agents for pathogenic proteins in diseases
Publications	Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2, Jing Yang, Yiying Xue, Husheng Mei, Yisa Chen, James D. Griffin, Qingsong Liu, Ellen Weisberg, 2023 Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19, Jing Yang, Yisa Chen, Yiying Xue, 2023 Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer, Jing Yang, Husheng Mei, Hong Wu, Bin Zhou, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Zuowei Wang, Wenchao Wang, Jing Liu, Qingsong Liu, 2023 Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2, Jing Yang, Ellen L. Weisberg, Shuang Qi, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage, Qingsong Liu, James D. Griffin, 2022 Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2, Jing Yang, Ellen L. Weisberg, Xiaoxi Liu, Robert Magin, Wai Cheung Chan, Bin Hu, Nathan Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod Marto, James Griffin, Sara Buhrlage, 2022 The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation, Jing Yang, Ping Wei, Joseph Barbi, Qianru Huang, Evan Yang, Yakun Bai, Jia Nie, Yanhang Gao, Jinhui Tao, Ying Lu, Chichu Xie, Xiaoxia Hou, Jiazi Ren, Xingmei Wu, Jian Meng, Ying Zhang, Juan Fu, Wei Kou, Yayi Gao, Zuojia Chen, Rui Liang, Andy Tsun, Dan Li, Wenzhi Guo, Shuijun Zhang, Song-Guo Zheng, Junqi Niu, Paul Galardy, Xuemei Tong, Guochao Shi, Huabin Li, Fan Pan, Bin Li, 2020 Inhibition of the deubiquitinase USP10 induces degradation of SYK, Jing Yang, Chengcheng Meng, Ellen L. Weisberg, Ilaria Lamberto, Martin Sattler, Nathanael S. Gray, Sara J. Buhrlage, James D. Griffin, 2020 HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance, Jing Yang, Ellen L. Weisberg, 2021 Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt, Jing Yang, Peng Xu, Lei Han, Zhixiang Guo, Xiuwen Wang, Zuojia Chen, Jia Nie, Shuying Yin, Miranda Piccioni, Andy Tsun, Ling Lv, Shenglin Ge, Bin Li, 2015 TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression, Jing Yang, Xiuwen Wang, Lei Han, Kaixia Zhao, Qingsi Wu, Zhiyuan Li, Ling Lv, Bin Li, 2015 The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells, Jing Yang, Lei Han, Xiuwen Wang, Shuying Yin, Zhiyuan Li, Jing Zhang, Yue Xing, Zuojia Chen, Andy Tsun, Dan Li, Miranda Piccioni, Yu Zhang, Qiang Guo, Lindi Jiang, Liming Bao, Ling Lv, Bin Li, 2014

Areas of Focus

Targeted and immunotherapy for malignant diseases such as leukemia
Discovery and development of degrading agents for pathogenic proteins in diseases

Publications

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-COV-2, Jing Yang, Yiying Xue, Husheng Mei, Yisa Chen, James D. Griffin, Qingsong Liu, Ellen Weisberg, 2023
Gilteritinib: Repurposing of AXL-targeting kinase inhibitors against COVID-19, Jing Yang, Yisa Chen, Yiying Xue, 2023
Discovery of IHMT-337 as a potent irreversible inhibitor targeting novel noncanonical role of EZH2 for triple-negative breast cancer, Jing Yang, Husheng Mei, Hong Wu, Bin Zhou, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Zuowei Wang, Wenchao Wang, Jing Liu, Qingsong Liu, 2023
Inhibition of deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2, Jing Yang, Ellen L. Weisberg, Shuang Qi, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J. Buhrlage, Qingsong Liu, James D. Griffin, 2022
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2, Jing Yang, Ellen L. Weisberg, Xiaoxi Liu, Robert Magin, Wai Cheung Chan, Bin Hu, Nathan Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod Marto, James Griffin, Sara Buhrlage, 2022
The deubiquitinase USP44 promotes Treg function during inflammation by preventing FOXP3 degradation, Jing Yang, Ping Wei, Joseph Barbi, Qianru Huang, Evan Yang, Yakun Bai, Jia Nie, Yanhang Gao, Jinhui Tao, Ying Lu, Chichu Xie, Xiaoxia Hou, Jiazi Ren, Xingmei Wu, Jian Meng, Ying Zhang, Juan Fu, Wei Kou, Yayi Gao, Zuojia Chen, Rui Liang, Andy Tsun, Dan Li, Wenzhi Guo, Shuijun Zhang, Song-Guo Zheng, Junqi Niu, Paul Galardy, Xuemei Tong, Guochao Shi, Huabin Li, Fan Pan, Bin Li, 2020
Inhibition of the deubiquitinase USP10 induces degradation of SYK, Jing Yang, Chengcheng Meng, Ellen L. Weisberg, Ilaria Lamberto, Martin Sattler, Nathanael S. Gray, Sara J. Buhrlage, James D. Griffin, 2020
HSP70 and FLT3-ITD: targeting chaperone system to overcome drug resistance, Jing Yang, Ellen L. Weisberg, 2021
Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt, Jing Yang, Peng Xu, Lei Han, Zhixiang Guo, Xiuwen Wang, Zuojia Chen, Jia Nie, Shuying Yin, Miranda Piccioni, Andy Tsun, Ling Lv, Shenglin Ge, Bin Li, 2015
TRAF5 Mediated K63-linked Polyubiquitination Plays an Essential Role in the Positive regulation of RORγt on promoting IL-17A Expression, Jing Yang, Xiuwen Wang, Lei Han, Kaixia Zhao, Qingsi Wu, Zhiyuan Li, Ling Lv, Bin Li, 2015
The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells, Jing Yang, Lei Han, Xiuwen Wang, Shuying Yin, Zhiyuan Li, Jing Zhang, Yue Xing, Zuojia Chen, Andy Tsun, Dan Li, Miranda Piccioni, Yu Zhang, Qiang Guo, Lindi Jiang, Liming Bao, Ling Lv, Bin Li, 2014

Leukemia Malignant Diseases Targeted Therapy Immunotherapy Protein Degradation Pathogenic Proteins Dub E3 Ligases Drug Development Resistance Mechanisms

Yunhua Peng - Xi'an Jiaotong University

Zhuo Chen - University of Chinese Academy of Sciences

Youhai Chen - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us